New Patented Medicines Reported to PMPRB

Up to date as of July 8, 2020

Search by:

to

* Note: Drugs with Price Review Records linked from the brand name are only available from 2010 onward (records for 2011 will be populated over the next few months). Summary Reports are available for drug products reported prior to 2010.


YearCompanyBrand NameChemical NameDINTherapeutic UseDate of First SaleStatus
2018AbbVie (a Division of Abbott Laboratories, Limited)Orilissa - 150 mg/tabletelagolix (elagolix sodium)02481332moderate to severe pain associated with endometriosis30 Oct 2018Within Guidelines
2018Aerie Pharmaceuticals, Inc.Rhopressa - 0.2 mg/mLnetarsudilreduction of elevated intraocular pressure (IOP)06 Nov 2018Within Guidelines
2018Alexion Pharmaceuticals Inc.KANUMA - 2 mg/mLsebelipase alfa2469596Lysosomal acid lipase deficiency10 Apr 2018Within Guidelines
2018Alexion Pharmaceuticals Inc.STRENSIQ - 40 mg/mLasfotase alfa2444631Paediatric-onset Hypophosphatasia23 Jan 2018Does Not Trigger Investigation
2018Allergan Inc.Restasis Multidose - 0.5 mg/mLcyclosporine02476835moderate to moderately severe aqueous deficient dry eye disease09 Jul 2018Within Guidelines
2018Allergan Inc.CONSTELLA - 72 mcg/capsulelinaclotide2469510Irritable bowel syndrome30 Mar 2018Within Guidelines
2018Amicus Therapeutics UK Ltd.Galafold - 123 mg/capsulemigalastat hydrochloride2468042Fabry disease14 Jan 2018Subject to Investigation
2018AstraZeneca Canada Inc.Imfinzi - 50 mg/mLdurvalumab2468816Cancer20 Nov 2017 (Patented 27 Feb 2018)Within Guidelines
2018AstraZeneca Canada Inc.LYNPARZA - 100 mg/tabletolaparib2475200Cancer23 May 2018VCU
2018AstraZeneca Canada Inc.LYNPARZA - 150 mg/tabletolaparib2475219Cancer23 May 2018VCU
2018AstraZeneca Canada Inc.FASENRA - 30 mg/dosebenralizumab2473232Eosinophilic asthma28 Mar 2018Within Guidelines
2018Avir Pharma Inc.ZEVTERA - 500 mg/vialceftobiprole medocaril2446685Pneumonia21 Mar 2018Within Guidelines
2018Avir Pharma Inc.Cresemba - 200 mg/vialisavuconazole (isavuconazonium sulfate)02483998antifungal19 Oct 2018Within Guidelines
2018Bausch Health, Canada Inc.Siliq - 210 mg/syringebrodalumab02473623moderate to severe plaque psoriasis05 Jul 2018Within Guidelines
2018Baxalta Canada CorporationRixubis - 3000 unit/vialnonacog gamma2431963Hemophilia B5 Dec 2017Subject to Investigation
2018Bayer Inc.Xarelto - 2.5 mg/tabletrivaroxaban02480808prevention of venous thromboembolic events28 Sep 2018Within Guidelines
2018Bristol-Myers Squibb Canada Co.Opdivo - 100 mg/vialnivolumab02446634unresectable or metastatic BRAF V600 wild-type melanoma26 Oct 2015Within Guidelines
2018Bristol-Myers Squibb Canada Co.Opdivo - 40 mg/vialnivolumab02446626unresectable or metastatic BRAF V600 wild-type melanoma26 Oct 2015Within Guidelines
2018Cipher Pharmaceuticals Inc.BRINAVESS - 20 mg/mLvernakalant hydrochloride2462400Atrial fibrillation23 Jan 2018Within Guidelines
2018Cipher Pharmaceuticals Inc.Ozanex - 10 mg/gramozenoxacin2463504Impetigo4 Jan 2018Within Guidelines
2018Eisai LimitedLenvima - 8 mg/daylenvatinib mesylate2468220Cancer7 May 2018Within Guidelines
2018Eisai LimitedLenvima - 18 mg/daylenvatinib mesylate2468239Cancer7 May 2018Within Guidelines
2018Eli Lilly Canada Inc.LARTRUVO - 500 mg/vialolaratumab2469227Cancer22 Dec 2017Subject to Investigation
2018Eli Lilly Canada Inc.Olumiant - 2 mg/tabletbaricitinib02480018moderate to severe rheumatoid arthritis27 Sep 2018Within Guidelines
2018EMD Serono Canada Inc.BAVENCIO - 20 mg/mLavelumab2469723Cancer19 Dec 2017Within Guidelines
2018Gilead Sciences, Inc.Biktarvy 25/50/200 - 275 mg/tabletbictegravir (bictegravir sodium)/emtricitabine/tenofovir alafenamide (tenofovir alafenamide hemifumarate)02478579human immunodeficiency virus-108 Aug 2018Within Guidelines
2018GlaxoSmithKline Inc.BENLYSTA - 200 mg/mLbelimumab2470489Lupus14 May 2018Subject to Investigation
2018GlaxoSmithKline Inc.Shingrix - 50 mcg/doseherpes zoster vaccine (non-live recombinant, AS01B adjuvanted)2468425Shingles2 Jan 2018Subject to Investigation
2018GlaxoSmithKline Inc.TRELEGY ELLIPTA 100/62.5/25 - 187.5 mcg/dosefluticasone furoate/umeclidinium/vilanterol2474522Chronic obstructive pulmonary disease30 May 2018Within Guidelines
2018Hoffmann-La Roche LimitedRituxan SC - 120 mg/mLrituximab2473976Cancer24 Apr 2018Within Guidelines
2018Hoffmann-La Roche LimitedAlecensaro - 150 mg/capsulealectinib2458136Cancer14 Oct 2016 (Patented 2 Jan 2018)Within Guidelines
2018Hoffmann-La Roche Limited, Canada Kadcyla - 160 mg/vialtrastuzumab emtansine02473224HER2-positive, metastatic breast cancer24 Oct 2018Does Not Trigger Investigation
2018Hoffmann-La Roche Limited, CanadaHerceptin Sc - 600 mg/vialtrastuzumab02480697early stage breast cancer15 Oct 2018Does Not Trigger Investigation
2018Ipsen Biopharmaceuticals Canada Inc.Cabometyx - 60 mg/tabletcabozantinib (cabozantinib malate)02480840Cancer10 Oct 2018Within Guidelines
2018Ipsen Biopharmaceuticals Canada Inc.Cabometyx - 40 mg/tabletcabozantinib (cabozantinib malate)02480832Cancer10 Oct 2018Within Guidelines
2018Ipsen Biopharmaceuticals Canada Inc.Cabometyx - 20 mg/tabletcabozantinib (cabozantinib malate)02480824Cancer10 Oct 2018Within Guidelines
2018Janssen Inc.Erleada - 60 mg/tabletapalutamide02478374non-metastatic castration-resistant prostate cancer27 Jul 2018Within Guidelines
2018Janssen Inc.Darzalex - 400 mg/vialdaratumumab02455978Cancer12 Jul 2016Within Guidelines
2018Janssen Inc.Darzalex - 100 mg/vialdaratumumab02455951Cancer12 Jul 2016Within Guidelines
2018Janssen Inc.SYMTUZA 800/150/200/10 - 1160 mg/tabletdarunavir/cobicistat/emtricitabine/tenofovir alafenamide2473720HIV26 Apr 2018VCU
2018Knight Therapeutics Inc.Probuphine - 80 mg/implantbuprenorphine hydrochloride02474921opioid dependence22 Nov 2018Within Guidelines
2018Laboratoires ThéaMONOPROST - 50 mcg/mLlatanoprost2456230Intraocular pressure3 Jan 2018Within Guidelines
2018Mallinckrodt Pharmaceuticals, LLCOFIRMEV - 10 mg/mLacetaminophen2408066Pain10 May 2018Subject to Investigation
2018Medexus Inc.Metoject Subcutaneous - 15 mg/syringemethotrexate (methotrexate sodium)02454858Severe disabling psoriasis/psoriatic arthritis and Severe disabling rheumatoid arthritis30 Nov 2018Subject to Investigation
2018Merck Canada Inc.Pifeltro - 100 mg/tabletdoravirine02481545human immunodeficiency virus-114 Nov 2018Under Review
2018Merck Canada Inc.Steglujan 5/100 - 105 mg/tabletertugliflozin/sitagliptin (sitagliptin phosphate)02475901type 2 diabetes mellitus14 Jun 2018Within Guidelines
2018Merck Canada Inc.Steglujan 15/100 - 115 mg/tabletertugliflozin/sitagliptin (sitagliptin phosphate)02475928type 2 diabetes mellitus14 Jun 2018Within Guidelines
2018Merck Canada Inc.Segluromet 7.5/500 - 507.5 mg/tabletertugliflozine/chlorhydrate de metformine02476231type 2 diabetes mellitus06 Jul 2018Within Guidelines
2018Merck Canada Inc.Segluromet 7.5/1000 - 1007.5 mg/tabletertugliflozin/metformin hydrochloride02476258type 2 diabetes mellitus06 Jul 2018Within Guidelines
2018Merck Canada Inc.Segluromet 2.5/500 - 502.5 mg/tabletertugliflozin/metformin hydrochloride02476215type 2 diabetes mellitus06 Jul 2018Within Guidelines
2018Merck Canada Inc.Segluromet 2.5/1000 - 1002.5 mg/tabletertugliflozin/metformin hydrochloride02476223type 2 diabetes mellitus06 Jul 2018Within Guidelines
2018Merck Canada Inc.STEGLATRO - 5 mg/tabletertugliflozin2475510Diabetes28 May 2018Within Guidelines
2018Merck Canada Inc.STEGLATRO - 15 mg/tabletertugliflozin2475529Diabetes28 May 2018Within Guidelines
2018Merck Canada Inc.PREVYMIS - 20 mg/mLletermovir2469367Antiviral20 Dec 2017Subject to Investigation
2018Merck Canada Inc.PREVYMIS - 240 mg/tabletletermovir2469375Antiviral20 Dec 2017Subject to Investigation
2018Merck Canada Inc.PREVYMIS - 480 mg/tabletletermovir2469383Antiviral20 Dec 2017Subject to Investigation
2018Merck Canada Inc.PREVYMIS - 20 mg/mLletermovir2469405Antiviral20 Dec 2017Subject to Investigation
2018Novartis Pharmaceuticals Canada Inc.PAZEO - 7 mg/mLolopatadine hydrochloride2458551Ocular itching12 Mar 2018Within Guidelines
2018Novartis Pharmaceuticals Canada Inc.Kisqali - 200 mg/tabletribociclib2473569Cancer26 Apr 2018Within Guidelines
2018Novartis Pharmaceuticals Canada Inc.Arzerra - 1000 mg/mLofatumumab02381567chronic lymphocytic leukemia14 May 2014Within Guidelines
2018Novartis Pharmaceuticals Canada Inc.Arzerra - 100 mg/mLofatumumab02381559chronic lymphocytic leukemia14 May 2014Within Guidelines
2018Novo Nordisk Canada Inc.Ozempic - 1 mg/dosesemaglutide2471469Diabetes23 Feb 2018Within Guidelines
2018Novo Nordisk Canada Inc.Ozempic - 1 N.A./dosesemaglutide2471477Diabetes23 Feb 2018Does Not Trigger Investigation
2018Novo Nordisk Canada Inc.Rebinyn - 500 N.A./IUnonacog beta pegol2470187Hemophilia B4 Apr 2018Within Guidelines
2018Novo Nordisk Canada Inc.Rebinyn - 1000 N.A./IUnonacog beta pegol2470268Hemophilia B4 Apr 2018Within Guidelines
2018Novo Nordisk Canada Inc.Rebinyn - 2000 N.A./IUnonacog beta pegol2470276Hemophilia B4 Apr 2018Within Guidelines
2018Novo Nordisk Canada Inc.Zonovate - 250 N.A./IUturoctocog alfa2435187Hemophilia A2 Apr 2018Within Guidelines
2018Novo Nordisk Canada Inc.Zonovate - 500 N.A./IUturoctocog alfa2435195Hemophilia A2 Apr 2018Within Guidelines
2018Novo Nordisk Canada Inc.Zonovate - 1000 N.A./IUturoctocog alfa2435209Hemophilia A3 Apr 2018Within Guidelines
2018Novo Nordisk Canada Inc.Zonovate - 2000 N.A./IUturoctocog alfa2435225Hemophilia A3 Apr 2018Within Guidelines
2018Novo Nordisk Canada Inc.Zonovate - 3000 N.A./IUturoctocog alfa2435233Hemophilia A3 Apr 2018Within Guidelines
2018Octapharma Canada Inc.Nuwiq - 4000 IU/vialsimoctocog alfa02474069hemophilia A (congenital factor VIII deficiency)25 Jul 2018Within Guidelines
2018Octapharma Canada Inc.Nuwiq - 3000 IU/vialsimoctocog alfa02474050hemophilia A (congenital factor VIII deficiency)25 Jul 2018Within Guidelines
2018Pfizer Canada Inc.Eucrisa - 20 mg/gramcrisaborole02476991mild to moderate atopic dermatitis30 Oct 2018Within Guidelines
2018Pfizer Canada Inc.TRUMENBA - 60/60 - 120 mcg/syringeneisseria meningitidis group B recombinant lipoprotein 2086 subfamily A/B2468751Invasive meningococcal disease31 Jan 2018Within Guidelines
2018Pfizer Canada Inc.XELJANZ XR -- 11 mg/tablettofacitinib citrate2470608Rheumatoid arthritis29 Mar 2018Does Not Trigger Investigation
2018Pfizer Canada Inc.BESPONSA - 0.9 mg/vialinotuzumab ozogamicin2473909Cancer3 May 2018Within Guidelines
2018Purdue PharmaBELBUCA - 75 mcg/filmbuprenorphine hydrochloride2465221Pain17 Jan 2018Within Guidelines
2018Purdue PharmaBELBUCA - 150 mcg/filmbuprenorphine hydrochloride2465248Pain17 Jan 2018Within Guidelines
2018Purdue PharmaBELBUCA - 300 mcg/filmbuprenorphine hydrochloride2465256Pain17 Jan 2018Within Guidelines
2018Purdue PharmaBELBUCA - 450 mcg/filmbuprenorphine hydrochloride2465264Pain17 Jan 2018Within Guidelines
2018Purdue PharmaFoquest - 25 mg/capsulemethylphenidate hydrochloride2470292ADHD14 Dec 2017Within Guidelines
2018Purdue PharmaFoquest - 35 mg/capsulemethylphenidate hydrochloride2470306ADHD14 Dec 2017Within Guidelines
2018Purdue PharmaFoquest - 45 mg/capsulemethylphenidate hydrochloride2470314ADHD14 Dec 2017Within Guidelines
2018Purdue PharmaFoquest - 55 mg/capsulemethylphenidate hydrochloride2470322ADHD14 Dec 2017Within Guidelines
2018Purdue PharmaFoquest - 70 mg/capsulemethylphenidate hydrochloride2470330ADHD14 Dec 2017Within Guidelines
2018Purdue PharmaFoquest - 85 mg/capsulemethylphenidate hydrochloride2470349ADHD14 Dec 2017Within Guidelines
2018Purdue PharmaFoquest - 100 mg/capsulemethylphenidate hydrochloride2470357ADHD11 Jan 2018Within Guidelines
2018Sanofi-Aventis Canada Inc.Dupixent - 150 mg/mLdupilumab2470365Atopic dermatitis7 Feb 2018VCU
2018Sanofi-aventis Canada Inc.Soliqua - 3 /peninsulin glargine/lixisenatide02478293type 2 diabetes mellitus12 Sep 2018Does Not Trigger Investigation
2018Sanofi-Aventis Canada Inc.Praluent - 75 mg/mL (syringe)alirocumab2453754Cholesterol13 Aug 2016 (Patented 9 Jan 2018)VCU
2018Sanofi-Aventis Canada Inc.Praluent - 150 mg/mL (syringe)alirocumab2453762Cholesterol13 Aug 2016 (Patented 9 Jan 2018)VCU
2018Sanofi-Aventis Canada Inc.Praluent - 75 mg/mL (pen)alirocumab2453819Cholesterol18 May 2016 (Patented 9 Jan 2018)VCU
2018Sanofi-Aventis Canada Inc.Praluent - 150 mg/mL (pen)alirocumab2453835Cholesterol29 Apr 2016 (Patented 9 Jan 2018)VCU
2018Sanofi-aventis Canada Inc.Kevzara - 200 mg/pensarilumab02472988moderately to severely active rheumatoid arthritis21 Jun 2018Within Guidelines
2018Sanofi-aventis Canada Inc.Kevzara - 150 mg/pensarilumab02472961moderately to severely active rheumatoid arthritis21 Jun 2018Within Guidelines
2018Servier Canada Inc.Folotyn - 20 mg/mLpralatrexate02481820relapsed or refractory peripheral T-cell lymphoma04 Sep 2018Within Guidelines
2018Servier Canada Inc.Beleodaq - 500 mg/vialbelinostatLynphoma28 Nov 2018Within Guidelines
2018Shire Pharma Canada Inc. Takhzyro - 150 mg/mLlanadelumab02480948prevention of attacks of hereditary angioedema31 Oct 2018Subject to Investigation
2018Sprout PharmaceuticalsAddyi - 100 mg/tabletflibanserin02473550hypoactive sexual desire disorder13 Nov 2018Within Guidelines
2018Sunovion Pharmaceuticals Canada Inc.Cubicin RF - 500 mg/vialdaptomycin2465493Infections17 Jan 2018Does Not Trigger Investigation
2018Takeda Canada Inc.Alunbrig 90/180 - 1 N.A./packbrigatinib02479230Cancer31 Aug 2018Within Guidelines
2018Takeda Canada Inc.Alunbrig - 180 mg/tabletbrigatinib02479222Cancer31 Aug 2018Within Guidelines
2018Takeda Canada Inc.Alunbrig - 90 mg/tabletbrigatinib02479214Cancer31 Aug 2018Within Guidelines
2018Takeda Canada Inc.Alunbrig - 30 mg/tabletbrigatinib02479206Cancer31 Aug 2018Within Guidelines
2018Valeant Canada LpCONTRAVE 8/90 - 98 mg/tabletnaltrexone hydrochloride/bupropion hydrochloride2472945Chronic weight management16 Mar 2018Within Guidelines
2018Vertex Pharmaceuticals Canada Inc.Symdeko 100/150/150 - 1 N.A./packivacaftor/ivacaftor/tezacaftor02478080cystic fibrosis28 Jun 2018Within Guidelines
2018ViiV HealthCare ULCJuluca 50/25 - 75 mg/tabletdolutegravir (dolutegravir sodium)/rilpivirine (rilpivirine hydrochloride)02475774human immunodeficiency virus-104 Jun 2018Within Guidelines